Back to Browse Journals » Vascular Health and Risk Management » Volume 4 » Issue 5

Habitual coffee consumption and blood pressure: An epidemiological perspective

Authors Johanna M Geleijnse

Published Date August 2008 Volume 2008:4(5) Pages 963—970

DOI http://dx.doi.org/10.2147/VHRM.S3055

Published 5 August 2008

Johanna M Geleijnse

Division of Human Nutrition, Wageningen University, The Netherlands

Abstract: This paper summarizes the current epidemiological evidence on coffee consumption in relation to blood pressure (BP) and risk of hypertension. Data from crosssectional studies suggest an inverse linear or U-shaped association of habitual coffee use with BP in different populations. Prospective studies suggest a protective effect of high coffee intake (4 or more cups per day) against hypertension, mainly in women. Furthermore, the risk of hypertension may be lower in coffee abstainers. Randomized controlled trials, which are mostly of short duration (1–12 weeks), have shown that coffee intake around 5 cups per day causes a small elevation in BP (∼2/1 mmHg) when compared to abstinence or use of decaffeinated coffee. With regard to underlying biological mechanisms, most research has been devoted to BP-raising effects of caffeine. However, there are many other substances in coffee, such as polyphenols, soluble fi bre and potassium, which could exert a beneficial effect in the cardiovascular system. Although the precise nature of the relation between coffee and BP is still unclear, most evidence suggests that regular intake of caffeinated coffee does not increase the risk of hypertension.

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Readers of this article also read:

Cardiac allograft immune activation: current perspectives

Chang D, Kobashigawa J

Transplant Research and Risk Management 2015, 7:13-22

Published Date: 18 December 2014

Ex vivo and in vivo evaluation of an ultrasonic device for precise dissection, coagulation, and transection

Bertke BD, Scoggins PJ, Welling AL, Widenhouse TV, Chen C, Kallakuri S, Cavanaugh JM, Clymer JW, Amaral JF

Open Access Surgery 2015, 8:1-7

Published Date: 18 December 2014

Renal interstitial fibrosis induced by high-dose mesoporous silica nanoparticles via the NF-κB signaling pathway

Chen X, Zhouhua W, Jie Z, Xinlu F, Jinqiang L, Yuwen Q, Zhiying H

International Journal of Nanomedicine 2015, 10:1-22

Published Date: 18 December 2014

Transmyocardial revascularization devices: technology update

Kindzelski BA, Zhou Y, Horvath KA

Medical Devices: Evidence and Research 2015, 8:11-19

Published Date: 18 December 2014

Gentamicin-loaded nanoparticles show improved antimicrobial effects towards Pseudomonas aeruginosa infection

Abdelghany SM, Quinn DJ, Ingram RJ, Gilmore BF, Donnelly RF, Taggart CC, Scott CJ

International Journal of Nanomedicine 2012, 7:4053-4063

Published Date: 26 July 2012

Aminopropyltriethoxysilane-mediated surface functionalization of hydroxyapatite nanoparticles: synthesis, characterization, and in vitro toxicity assay

Wang S, Wen S, Shen M, Guo R, Cao X, Wang J, Shi X

International Journal of Nanomedicine 2011, 6:3449-3459

Published Date: 20 December 2011

Evaluating the effects of crystallinity in new biocompatible polyester nanocarriers on drug release behavior

Karavelidis V, Karavas E, Giliopoulos D, Papadimitriou S, Bikiaris D

International Journal of Nanomedicine 2011, 6:3021-3032

Published Date: 24 November 2011

Novel free paclitaxel-loaded poly(L-γ-glutamylglutamine)–paclitaxel nanoparticles

Danbo Yang, Sang Van, Xinguo Jiang, et al

International Journal of Nanomedicine 2011, 6:85-91

Published Date: 6 January 2011

Risk factors associated with methamphetamine use and heart failure among Native Hawaiians and other Pacific Island peoples

Marjorie K Mau, Karynna Asao, Jimmy Efird, Erin Saito, Robert Ratner, et al

Vascular Health and Risk Management 2009, 5:45-52

Published Date: 7 December 2008